Multiple genes relevant for the characterization, diagnosis, and manipulation of neuropathic pain
OwnerHermann Lubbert, Peter Engels +1inventors
InventorsHermann Lubbert, Peter Engels, Beate Schmitz
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of differentially expressed polynucleotide sequences or polypeptides for the characterization of pain status or progression, a method for characterizing pain, a method for identifying therapeutic agents for pain and the use of such sequences for the development of a medicament.
Claims31
A method for characterizing a pain status, comprising:
- a) detecting a level of expression of at least four gene sequences selected from the group consisting of SEQ ID NO. 1 to 64 or homologues or fragments thereof, in a test sample from an individual with pain;
- b) detecting a level of expression of said at least four gene sequences in a control sample;
- and
- c) comparing the levels of expression in the test and control samples, thereby characterizing the pain status.
A method for characterizing a pain status, comprising:
- a) providing a test sample comprising a cell or a body fluid expressing a polynucleotide sequence selected from the group consisting of SEQ ID NO. 1 to 64 or homologues or fragments thereof;
- b) detecting expression of said polynucleotide in said test sample;
- c) comparing the expression of said polynucleotide in said test sample to expression of the same polynucleotide in a reference sample whose expression stage is known;
- and
- d) identifying a difference in the levels of expression between said test sample and said reference sample, thereby characterizing the pain status.
A method for identifying a therapeutic agent for treating pain in a subject, comprising:
- a) providing a test cell capable of expressing a polynucleotide sequence selected from the group consisting of SEQ ID NO:
- 1 to 64 or homologues or fragments thereof;
- b) detecting expression of said polynucleotide sequence in said test cell;
- c) contacting said test cell with the therapeutic agent;
- d) detecting expression of said polynucleotide sequence in said test cell contacted with the therapeutic agent;
- e) comparing the expression of said polynucleotide sequence in step (b) to the expression of said polynucleotide sequence in step (d);
- and
- f) identifying a change in expression of said polynucleotide in the presence of the therapeutic agent, thereby identifying the therapeutic agent for treating pain.
A pharmaceutical composition, comprising a polynucleotide selected from the group consisting of SEQ ID NO:
- 1 to 64 or homologues or fragments thereof, or a polypeptide encoded by said polynucleotide.
A kit comprising a reagent for detecting a polynucleotide selected from the group consisting of SEQ ID NO:
- 1 to 64 or homologues or fragments thereof.
A vector, comprising a polynucleotide selected from the group consisting of SEQ ID NO:
- 1 to 64 or homologues or fragments thereof.
A host cell, comprising a polynucleotide selected from the group consisting of SEQ ID NO:
- 1 to 64 or homologues or fragments thereof.
An antibody that selectively binds to a polypeptide encoded by a polynucleotide selected from the group consisting of SEQ ID NO:
- 1 to 64 or homologues or fragments thereof.
A transgenic animal, comprising a polynucleotide selected from the group consisting of SEQ ID NO:
- 1 to 64 or homologues or fragments thereof, wherein said polynucleotide has been altered compared to a wild type phenotype.
Dependencies are inferred from the claim text.